Lujia Wang1, Minwei Zhou2, Chenchen Feng1, Peng Gao1, Guanxiong Ding1, Zhongwen Zhou3, Haowen Jiang1, Zhong Wu1, Qiang Ding4. 1. Department of Urology, Huashan Hospital of Fudan University, 12 Middle Wulumuqi Rd, Shanghai, 200040, People's Republic of China. 2. Department of General Surgery, Huashan Hospital of Fudan University, 12 Middle Wulumuqi Rd, Shanghai, 200040, People's Republic of China. 3. Department of Pathology, Huashan Hospital of Fudan University, 12 Middle Wulumuqi Rd, Shanghai, 200040, People's Republic of China. 4. Department of Urology, Huashan Hospital of Fudan University, 12 Middle Wulumuqi Rd, Shanghai, 200040, People's Republic of China. qiangding63@126.com.
Abstract
INTRODUCTION: Radical cystectomy (RC) is the gold standard treatment for patients with high-risk non-muscle-invasive bladder cancer and muscle-invasive bladder cancer (MIBC) . However, despite aggressive treatment, mortality rates of patients are still high. Therefore, it is crucial to indentify some practical prognostic factors for cancer-specific survival in those patients to guide our therapeutic strategies. MATERIALS AND METHODS: We included 103 patients treated with RC for urothelial bladder cancer (UBC) between July 2007 and June 2014 in our institution and analyzed their clinicopathological parameters. The mean follow-up was 22 months (range 2-89 months). RESULTS: Advanced tumor T stage, N stage, ABO blood type, a history of DM and positive p63 expression were independent factors for worse survival in all patients who underwent RC. Moreover, in female gender, high Ki67 expression was significant risk factor for cancer-specific survival (CSS) in MIBC patients. CONCLUSION: Our study demonstrated that immunohistochemical expressions of Ki67 and p63 are potential prognostic factors for UBC patients who underwent RC.
INTRODUCTION: Radical cystectomy (RC) is the gold standard treatment for patients with high-risk non-muscle-invasive bladder cancer and muscle-invasive bladder cancer (MIBC) . However, despite aggressive treatment, mortality rates of patients are still high. Therefore, it is crucial to indentify some practical prognostic factors for cancer-specific survival in those patients to guide our therapeutic strategies. MATERIALS AND METHODS: We included 103 patients treated with RC for urothelial bladder cancer (UBC) between July 2007 and June 2014 in our institution and analyzed their clinicopathological parameters. The mean follow-up was 22 months (range 2-89 months). RESULTS: Advanced tumor T stage, N stage, ABO blood type, a history of DM and positive p63 expression were independent factors for worse survival in all patients who underwent RC. Moreover, in female gender, high Ki67 expression was significant risk factor for cancer-specific survival (CSS) in MIBCpatients. CONCLUSION: Our study demonstrated that immunohistochemical expressions of Ki67 and p63 are potential prognostic factors for UBC patients who underwent RC.
Authors: Shahrokh F Shariat; Christian Bolenz; Guilherme Godoy; Yves Fradet; Raheela Ashfaq; Pierre I Karakiewicz; Hendrik Isbarn; Claudio Jeldres; Jérôme Rigaud; Arthur I Sagalowsky; Yair Lotan Journal: J Urol Date: 2009-05-17 Impact factor: 7.450
Authors: C A Goossens-Laan; O Visser; M W J M Wouters; M L E A Jansen-Landheer; J W W Coebergh; C J H van de Velde; M C C M Hulshof; P J M Kil Journal: Eur J Surg Oncol Date: 2010-07-02 Impact factor: 4.424
Authors: Tobias Klatte; Evanguelos Xylinas; Malte Rieken; Morgan Rouprêt; Harun Fajkovic; Christian Seitz; Pierre I Karakiewicz; Yair Lotan; Marko Babjuk; Michela de Martino; Shahrokh F Shariat Journal: Urol Oncol Date: 2014-02-02 Impact factor: 3.498
Authors: Wolfgang Otto; Matthias May; Hans-Martin Fritsche; Duska Dragun; Atiqullah Aziz; Michael Gierth; Lutz Trojan; Edwin Herrmann; Rudolf Moritz; Jörg Ellinger; Derya Tilki; Alexander Buchner; Thomas Höfner; Sabine Brookman-May; Philipp Nuhn; Christian Gilfrich; Jan Roigas; Mario Zacharias; Stefan Denzinger; Markus Hohenfellner; Axel Haferkamp; Stefan C Müller; Arkadius Kocot; Hubertus Riedmiller; Wolf F Wieland; Christian G Stief; Patrick J Bastian; Maximilian Burger Journal: Gend Med Date: 2012-12
Authors: Malte Rieken; Evanguelos Xylinas; Luis Kluth; Joseph J Crivelli; James Chrystal; Talia Faison; Yair Lotan; Pierre I Karakiewicz; Maxine Sun; Harun Fajkovic; Marek Babjuk; Alexander Bachmann; Douglas S Scherr; Shahrokh F Shariat Journal: Urol Oncol Date: 2013-10-17 Impact factor: 3.498
Authors: Sheng Wu; Katja Nitschke; Jakob Heinkele; Cleo-Aron Weis; Thomas Stefan Worst; Markus Eckstein; Stefan Porubsky; Philipp Erben Journal: Cancers (Basel) Date: 2019-11-21 Impact factor: 6.639
Authors: M C Kriegmair; R M Wirtz; T S Worst; J Breyer; M Ritter; B Keck; C Boehmer; W Otto; M Eckstein; C A Weis; A Hartmann; C Bolenz; P Erben Journal: Transl Oncol Date: 2018-02-23 Impact factor: 4.243
Authors: Peter Smittenaar; Alexandra K Walker; Shaun McGill; Christiana Kartsonaki; Rupesh J Robinson-Vyas; Janette P McQuillan; Sarah Christie; Leslie Harris; Jonathan Lawson; Elizabeth Henderson; Will Howat; Andrew Hanby; Gareth J Thomas; Selina Bhattarai; Lisa Browning; Anne E Kiltie Journal: Br J Cancer Date: 2018-07-11 Impact factor: 7.640